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Abstract Developing a validated tool for the rapid and effi-
cient assessment of cognitive functioning in HIV-infected pa-
tients in a typical outpatient clinical setting has been an unmet
goal of HIV research since the recognition of the syndrome of
HIV-associated dementia (HAD) nearly 20 years ago. In this
issue of JNIP Cross et al. report the application of the
International HIV Dementia Scale (IHDS) in a U.S.-based
urban outpatient clinic to evaluate its utility as a substitute for
the more time- and effort-demanding formalized testing criteria
known as the Frascati criteria that was developed in 2007 to
define the syndrome of HIV-associated neurocognitive disor-
ders (HAND). In this study an unselected cohort of 507 indi-
viduals (68 % African American) that were assessed using the
IHDS in a cross-sectional study revealed a 41 % prevalence of
cognitive impairment (labeled ‘symptomatic HAND’) that was
associated with African American race, older age, unemploy-
ment, education level, and depression. While the associations
between cognitive impairment and older age, education, unem-
ployment status and depression in HIV-infected patients are not
surprising, the association with African American ancestry and
cognitive impairment in the setting of HIV infection is a novel
finding of this study. This commentary discusses several im-
portant issues raised by the study, including the pitfalls of
assessing cognitive functioning with rapid screening tools,
cognitive testing criteria, normative testing control groups,
accounting for HAND co-morbidity factors, considerations
for clinical trials assessing HAND, and selective population
vulnerability to HAND.
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This study (Cross et al. 2013) clearly addresses several ex-
tremely important issues and raises important questions: how
can health-care professionals efficiently determine a patient’s
cognitive status during a routine clinical office visit to ulti-
mately formulate appropriate treatment plans? And, are
African Americans at a higher risk for cognitive impairment
associated with HIV infection? This begs an earnest discus-
sion in the field that should now follow. The points for discus-
sion are not that the IHDS and the HAND diagnostic criteria
can be cross-validated, but whether the IHDS, or some variant
thereof, can adequately substitute for HAND diagnostic criteria
in a routine clinical practice, and particularly in African
American populations. How does one effectively evaluate
HV-infected patients with co-morbidity conditions for cogni-
tive testing in such a setting? How does one invoke HIV as a
causative agent in mediating cognitive impairment in such
individuals? Can the IHDS be used as a screening (not diagnos-
tic) tool for cognitive impairment in a resource-limiting setting
where neuropsychological testing is not routinely available?
To fully evaluate and appreciate the implication of this
study the clarity of the metrics for assigning cognitive dys-
function must be appreciated. The application of the term
‘HAND’ should conform to the Frascati diagnostic criteria
of Antinori et al. (2007). The need to assess the prevalence of
HAND in this population was a short fall of the study. Indeed,
cognitive dysfunction was determined using the specific
criteria of the IHDS, which are distinct from the Frascati
criteria. Among the 41 % of individuals found to be impaired
by IHDS criteria (labeled ‘symptomatic HAND’) in the cur-
rent study, the true prevalence of HAND sub-groups in this
cohort, and whether these cohorts necessarily define the syn-
drome of HAND was unclear. For validation of the IHDS as a
surrogate for the group of diagnostic criteria for HAND, the
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diagnosis of HAND must first be confirmed, including sub-
group analysis, to determine the functional relevance of the
IHDS assessment. To their credit, the authors clearly recog-
nize this limitation in their study. Furthermore, it is not clear
what percentage of the 41 % had functional impairment in
their activities of daily living (ADLs) that define the HAND
sub-group with functional impairment (Woods et al. 2009)
The article could appropriately be entitled ‘Identifying risk
factors for cognitive impairment in HIV-infected individuals
using the International HIV Dementia Scale’ .
Another point to consider is that this study was designed to
address cognitive assessments in a routine clinical setting, few
patient exclusion criteria were applied, which further distin-
guishes this study from others. Thus, while the study truly
complements other studies, it does not substitute for more
rigidly-controlled neuroAIDS treatment outcome studies, such
as those developed through the AIDS Clinical Trials Group
consortium for testing candidate neuroprotective drug therapies
(Sacktor et al. 2011; Schifitto et al. 2007a, b; Marra et al. 2009;
Schifitto et al. 2009). Although this complicates the interpreta-
tion and data analysis, this study nonetheless ascertains data that
likely have intrinsic value for determining the at-large problem
that practicing clinicians face daily. Certainly, scientific rigor
must be applied to determine the significance of the findings.
Among the critical questions to ask are what is the control group
against which demographically-defined test groups are mea-
sured? First, if African-American ancestry is presented as a risk
factor forHIV-associated cognitive dysfunction, can one confirm
that HIV infection presents a higher risk for cognitive dysfunc-
tion in African-Americans evaluated in this clinical setting than
in the white/Caucasian group similarly evaluated? Are African-
Americans more vulnerable to damaging effects of CNS HIV
infection? Does the IHDS have demographically-adjusted nor-
mative scoring for African-Americans to determine this?
Second, another obvious question is how these results
compare with previous studies of risk factors for HIV cogni-
tive impairment. The most generally accepted biomarker for
increased risk for developing cognitive impairment in HIV
infected individuals is the historical CD4 T lymphocyte nadir
(Heaton et al. 2011; Ellis et al. 2011), which approached but
did not reach statistical significance in this study. Nonetheless,
the comparison in this study is probably informative, when
one considers that a largely unselected patient population was
studied. The authors mention other ‘traditional’ risk factors for
cognitive impairment, including age, race, education, depres-
sion, and income level. Each of these has been suggested as a
risk factor for HAND in previously published studies, which
also suggests that this study indeed reflects several validated
associations, even though the correlation with CD4 nadir was
not significant.
Of course, the conclusion that African-American ancestry
is a significant risk factor for HAND will surely and appro-
priately prompt robust discussions. The authors cite other
published studies that suggest that co-morbidities within the
African-American population, such as a metabolic syndrome
of cardiovascular disease and diabetes, might account for
increased risk for cognitive impairment independent of HIV
infection. Whether the putative independent risk of HIV in-
fection for cognitive impairment in African Americans sug-
gested in this study reflects the high risk of metabolic syn-
drome in HIV-infected African Americans is presented as a
possibility. Both cardiovascular disease and diabetes are more
prevalent in HIV-infected individuals (Samaras 2012; Boccara
and Cohen 2003), but whether HIV infection alone is a par-
ticularly stronger risk factor for cognitive impairment in
African-Americans will clearly require further detailed study.
The problem of validating a rapid and simple diagnostic
approach for identifying HIV-infected individuals at risk for
HAND in 2013 directly depends on the features of cognitive
impairment in the setting of anti-retroviral therapy (ART), and
at least indirectly on the pathological substrate of brain dam-
age in such individuals. HIV encephalitis is now distinctly
uncommon, in contrast to the pre-ART era, and HIV-
associated brain injury likely develops more chronically in a
setting of smoldering low-level activation and inflammation
(Gelman et al. 2013; Everall et al. 2009). A major gap in our
understanding of HAND (as strictly defined by Frascati
criteria) and its risk factors in the era of ART is the relative
contribution of virus replication in the brain. Many patients
receiving cART and having the diagnosis of HAND have
sustained suppression of peripheral viral load, which raises
the question as to how much the virus is now contributing to
HAND in such patients (Heaton et al. 2011. It is therefore
getting increasingly difficult to confirm progressive cognitive
impairment due to HIV infection per se and thus identify
patients for whom neuroprotective therapies in addition to
ART might be helpful. It must be noted that the benefit of
prolonged lifespan due to ART also increases risk for age-
associated neurodegeneration risk factors. Paradoxically de-
spite sustained suppression of virus replication, chronic im-
mune activation in the CNS and systemic compartments per-
sist and is linked to chronic disease progression (Burdo et al.
2013; Deeks 2011; Pulliam et al. 1997; Ancuta et al. 2008;
Kraft-Terry et al. 2009). Furthermore, sustained ART treat-
ment is often associated with ‘blips’ of virus replication and
probably fluctuating levels of tissue inflammation, which in
turn, may have cumulative damaging effects on the host
(Havlir et al. 2001).
Adding further complexity is the fact that HAND is often
accompanied by many co-morbidity factors such as
Hepatitis C infection, substance abuse, and medical con-
ditions associated with ART usage including hyperlipide-
mia, beta amyloid deposition, medications used for con-
trolling depression and anxiety, all of which individually
or in co-operation contribute to the development and pro-
gression of HAND, which is emerging as a multifactorial
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syndrome. In an immunocompetent host receiving ART
virus replication probably plays but a small contributing
role in this disorder. Additional additive factors such as
types of ART regimens, immunological, genetic and psy-
chosocial entities as well as brain injury prior to ART
could also contribute to the severity of cognitive dysfunc-
tion, thereby making it difficult to dissociate the effects of
HIV from other factors. A subset of patients receiving
cART also go on to develop a fulminant immune recon-
stitution syndrome, which can contribute further to brain
injury. A recent review by Alfahad & Nath (2013) is an
elegant update on the current thoughts on HAND.
An urgent need therefore exists in the field to develop a
universally agreed-upon clinical testing of day-to-day function-
ing of patients for use in the clinics (Blackstone et al. 2012a).
The existing tests that are available are based upon self-
reporting and can be confounded in the context of psychiatric
or socioeconomic factors (Blackstone et al. 2012b). More
recently there has been a report on Computer Assessment of
Mild Cognitive Impairment (CAMCI), a computer-based
screening tool that includes performance-based measures of
functional impairment (Rosenthal et al. 2013). While the ad-
vantages of neurosychological battery as the gold standard for
diagnosis of HAND cannot be disputed, its lack of availability
in resource-limiting settings where the burgeoning burden of
HIV infection prevails remains a serious concern. Moreover,
the exclusion criteria followed during this testing makes it
difficult to assess the effects of depression and pre-existing
cognitive impairment as modulators of the disease. Having said
that, in the absence of any other universal HAND testing,
neurospyschological testing does remain the gold standard for
the diagnosis of HAND. Nonetheless, obtaining normative
neurospsychological test data for multifactorial disease such
as HAND with its comorbid confounds also continues to be a
challenge. Along with this, there is a critical need for identify-
ing risk factors that might predominate in particular sub-
populations at risk for HAND, such as African-Americans, as
suggested by this current study. Understanding the true preva-
lence of HAND and associated risk factors in patient sub-
populations can guide development of more effective neuro-
protective therapies in such populations. A recent review by
Kamminga et al. (2013) addresses the various strengths and
weaknesses of the existing tests for detection of HAND. Taken
together, the dilemma exists of the availability of comprehen-
sive neuropsychological testing available to the elite few versus
the use of IHDS and other such tests for rapid screening of
cognitive dysfunction targeted to a larger population in the
clinics. Such rapid tests could be a means to identify symptom-
atic impairment and its progression longitudinally in patients.
In summary, it must be emphasized that HAND is evolving
as a more complex entity and this therefore warrants urgent
investigations in the field aimed at development of sophisti-
cated diagnostic tools coupled with neuroimaging studies that
are appropriate for vulnerable patient populations in order to
define the natural history and test neuroprotective therapies.
Additionally, the diffuse nature of the disease that is known to
target various regions of the brain makes it a problem for
developing animal models to study the disease pathophysiol-
ogy and to develop effective neuroprotective therapies.
However, developing and validating novel rodent and non-
human primate models of HAND is still critical for under-
standing the disease pathogenesis and testing potential thera-
peutics (Fox and Gendelman 2012). Furthermore, testing neu-
roprotective drug efficacy against HAND also requires the
study of non-HIV-infected, at-risk human control groups shar-
ing co-morbidity factors with HIV-infected subjects to prop-
erly determine the relative contribution of HIV and other
factors to the genesis of HAND and the response to drugs.
Because patients with HAND continue to live long on cART,
diseases of the aging are now more common in individuals
with HAND it is imperative that such factors are also
accounted for in clinical studies. Because HAND presents a
major burden to many individuals living with HIV, efforts
aimed at both diagnosing and preventing HAND to improve
the quality of life of such individuals should be a healthcare
priority.
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